Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

M. Fonseca, Nicolette; Maurice‐Dror, Corinne; Herberts, Cameron; Tu, Wilson; R. S. Fan, William; J. Murtha, Andrew; Kollmannsberger, Catarina; M. Kwan, Edmond; Parekh, Karan; Schönlau, Elena; Q. Bernales, Cecily; Donnellan, Gráinne; W.S. Ng, Sarah; Sumiyoshi, Takayuki; Vergidis, Joanna; Noonan, Krista; L. Finch, Daygen; Zulfiqar, Muhammad; Miller, Stacy; Parimi, Sunil; Lavoie, Jean‐Michel; Hardy, Edward; Soleimani, Maryam; Nappi, Lucia; J. Eigl, Bernhard; Kollmannsberger, Christian; Taavitsainen, Sinja; Nykter, Matti; H. Tolmeijer, Sofie; Boerrigter, Emmy; Mehra, Niven; P. van Erp, Nielka; De Laere, Bram; Lindberg, Johan; Grönberg, Henrik; Khalaf, Daniel; Annala, Matti; N., Kim; W. Wyatt, Alexander

doi:10.1038/s41467-024-45475-w

Public

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Published in Nature Communications • Feb 28, 2024

Authors:

Nicolette M. Fonseca

Corinne Maurice‐Dror

Cameron Herberts

Abstract

No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outc...

Subject

Medicine

Prostate cancer

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!